Evommune (EVMN) Free Cash Flow (2024 - 2026)

Evommune (EVMN) has 3 years of Free Cash Flow data on file, last reported at -$27.6 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$27.6 million, down 15.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$68.1 million (changed N/A YoY), and the FY2025 annual result was -$76.5 million, down 31.21% from the prior year.
• Free Cash Flow declined to -$27.6 million in Q1 2026 per EVMN's latest filing, from -$16.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$16.6 million in Q4 2025 and troughed at -$27.6 million in Q1 2026.
• A 3-year average of -$21.6 million and a median of -$21.2 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow rose 10.31% in 2025, then dropped 15.43% in 2026.
• A 3-year view of Free Cash Flow shows it stood at -$18.5 million in 2024, then advanced by 10.31% to -$16.6 million in 2025, then tumbled by 66.15% to -$27.6 million in 2026.
• Business Quant data shows EVMN's Free Cash Flow at -$27.6 million in Q1 2026, -$16.6 million in Q4 2025, and -$23.9 million in Q1 2025.